202 related articles for article (PubMed ID: 32484237)
1. Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
Sankatsing VDV; van Ravesteyn NT; Heijnsdijk EAM; Broeders MJM; de Koning HJ
Int J Cancer; 2020 Dec; 147(11):3059-3067. PubMed ID: 32484237
[TBL] [Abstract][Full Text] [Related]
2. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
4. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
Trentham-Dietz A; Chapman CH; Jayasekera J; Lowry KP; Heckman-Stoddard BM; Hampton JM; Caswell-Jin JL; Gangnon RE; Lu Y; Huang H; Stein S; Sun L; Gil Quessep EJ; Yang Y; Lu Y; Song J; Muñoz DF; Li Y; Kurian AW; Kerlikowske K; O'Meara ES; Sprague BL; Tosteson ANA; Feuer EJ; Berry D; Plevritis SK; Huang X; de Koning HJ; van Ravesteyn NT; Lee SJ; Alagoz O; Schechter CB; Stout NK; Miglioretti DL; Mandelblatt JS
JAMA; 2024 Jun; 331(22):1947-1960. PubMed ID: 38687505
[TBL] [Abstract][Full Text] [Related]
5. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.
van Ravesteyn NT; Miglioretti DL; Stout NK; Lee SJ; Schechter CB; Buist DS; Huang H; Heijnsdijk EA; Trentham-Dietz A; Alagoz O; Near AM; Kerlikowske K; Nelson HD; Mandelblatt JS; de Koning HJ
Ann Intern Med; 2012 May; 156(9):609-17. PubMed ID: 22547470
[TBL] [Abstract][Full Text] [Related]
6. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.
Chootipongchaivat S; Wong XY; Ten Haaf K; Hartman M; Tan KB; van Ravesteyn NT; Wee HL
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):653-660. PubMed ID: 33531436
[TBL] [Abstract][Full Text] [Related]
8. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
9. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.
Shih YT; Dong W; Xu Y; Etzioni R; Shen Y
Ann Intern Med; 2021 May; 174(5):602-612. PubMed ID: 33556275
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of digital breast tomosynthesis in a population breast cancer screening program.
Wang J; Phi XA; Greuter MJW; Daszczuk AM; Feenstra TL; Pijnappel RM; Vermeulen KM; Buls N; Houssami N; Lu W; de Bock GH
Eur Radiol; 2020 Oct; 30(10):5437-5445. PubMed ID: 32382844
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program.
Wang J; Greuter MJW; Vermeulen KM; Brokken FB; Dorrius MD; Lu W; de Bock GH
Breast; 2022 Feb; 61():58-65. PubMed ID: 34915447
[TBL] [Abstract][Full Text] [Related]
12. Insights Into Breast Cancer Screening: A Computer Simulation of Two Contemporary Screening Strategies.
Carter KJ; Castro F; Morcos RN
AJR Am J Roentgenol; 2018 Mar; 210(3):564-571. PubMed ID: 29323554
[TBL] [Abstract][Full Text] [Related]
13. Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening.
Davidović M; Zielonke N; Lansdorp-Vogelaar I; Segnan N; de Koning HJ; Heijnsdijk EA
Value Health; 2021 Mar; 24(3):353-360. PubMed ID: 33641769
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
Sankatsing VDV; Juraniec K; Grimm SE; Joore MA; Pijnappel RM; de Koning HJ; van Ravesteyn NT
Radiology; 2020 Oct; 297(1):40-48. PubMed ID: 32749212
[TBL] [Abstract][Full Text] [Related]
15. Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study.
Alagoz O; Hajjar A; Chootipongchaivat S; van Ravesteyn NT; Yeh JM; Ergun MA; de Koning HJ; Chicoine B; Martin B
J Gen Intern Med; 2019 Nov; 34(11):2374-2381. PubMed ID: 31385214
[TBL] [Abstract][Full Text] [Related]
16. A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening.
Koleva-Kolarova RG; Daszczuk AM; de Jonge C; Abu Hantash MK; Zhan ZZ; Postema EJ; Feenstra TL; Pijnappel RM; Greuter MJW; de Bock GH
Maturitas; 2018 Mar; 109():81-88. PubMed ID: 29452787
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
18. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
19. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
